MAST

Guardsquare Augments Free Mobile App Security Testing Product With Enterprise-Ready Version

Retrieved on: 
Martedì, Maggio 7, 2024
Security, Mobile, Wireless, Apps, Applications, Technology, Software, DevOps, OWASP, SAST, Enterprise, Automation, MAST, Organization, IOS, Mobile phone

Guardsquare, the mobile application security provider, today announced the company’s award-winning free mobile application security testing (MAST) product, AppSweep, is now available in an enterprise version to help organizations scale their ability to find and address security risks across multiple teams working at different stages of mobile app builds.

Key Points: 
  • Guardsquare, the mobile application security provider, today announced the company’s award-winning free mobile application security testing (MAST) product, AppSweep, is now available in an enterprise version to help organizations scale their ability to find and address security risks across multiple teams working at different stages of mobile app builds.
  • AppSweep Enterprise facilitates access across teams, compliance with IT security policies and seamlessly integrates with existing tools and systems.
  • “I am proud of the ongoing evolution of AppSweep as we continue our quest to make mobile app security testing accessible to organizations of all sizes - now in both free and paid versions,” said Roel Caers, CEO of Guardsquare.
  • “AppSweep has become our go-to mobile applications security testing tool, with its low rate of false positives and actionable advice to avoid security issues,” says a leading financial services provider.

Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort

Retrieved on: 
Lunedì, Aprile 15, 2024
Cancer, Bile, FDA, Imugene, City, IMU, Immunotherapy, Recurrence, Breast, ASX, Conference, Thymic carcinoma, Disease, Patient, MAST, Lung, Pharmaceutical industry

Cholangiocarcinoma is a rare disease in which malignant cancer cells form in the bile ducts.

Key Points: 
  • Cholangiocarcinoma is a rare disease in which malignant cancer cells form in the bile ducts.
  • On Friday 12 April 2024, the Cohort Review Committee cleared the fifth cohort in the IT arm of the monotherapy dose escalation portion of the MAST trial, with no safety signals seen to date.
  • In addition to the patients dosed in the monotherapy dose escalation portion of the trial, enrolment is ongoing for the VAXINIA and pembrolizumab combination portion of the trial, with 16 patients dosed to date.
  • With no safety signals identified to date, the trial has since progressed through the monotherapy dose escalation cohorts as well as the combination study, whereby VAXINIA is administered with well-known checkpoint inhibitor pembrolizumab.

CAPTAIN PAUL WATSON FOUNDATION TO STOP KILLING OF ENDANGERED FIN WHALES IN ICELAND

Retrieved on: 
Martedì, Aprile 16, 2024
Storm, Ship, IWC, Sea Shepherd Conservation Society, Life, History, Whale, MAST, IUCN Red List, Threatened species, Fishery, Icelanders, International Whaling Commission, Whaling

ALBERT DOCK, HULL, England, April 16, 2024 /PRNewswire/ -- Captain Paul Watson Foundation is launching Operation Ice Storm from Albert Dock in Yorkshire to directly oppose Iceland's last whaling company, Hvalur hf. Paul Watson, a co-founder of Greenpeace and founder of Sea Shepherd, has a history of intervening in Icelandic whaling operations - In 1986, members of his group successfully reduced the whaling fleet of Hvalur hf by half.

Key Points: 
  • ALBERT DOCK, HULL, England, April 16, 2024 /PRNewswire/ -- Captain Paul Watson Foundation is launching Operation Ice Storm from Albert Dock in Yorkshire to directly oppose Iceland's last whaling company, Hvalur hf.
  • "The time is up for the world's most notorious hunter of whales, Kristján Loftsson," stated Captain Paul Watson, who will lead this summer's anti-whaling campaign on his flagship the John Paul DeJoria, a 72-meter former Scottish Fisheries Protection Vessel.
  • The whaler's business empire includes large shareholdings in banks and IT companies and the magnate uses his wealth to hunt up to 209 fin whales each season.
  • Fin whales are protected under international conservation law and listed as vulnerable on the IUCN Red List of Threatened Species.

CAPTAIN PAUL WATSON FOUNDATION TO STOP KILLING OF ENDANGERED FIN WHALES IN ICELAND

Retrieved on: 
Martedì, Aprile 16, 2024
Storm, Ship, IWC, Sea Shepherd Conservation Society, Life, History, Whale, MAST, IUCN Red List, Threatened species, Fishery, Icelanders, International Whaling Commission, Whaling

ALBERT DOCK, HULL, England, April 16, 2024 /PRNewswire/ -- Captain Paul Watson Foundation is launching Operation Ice Storm from Albert Dock in Yorkshire to directly oppose Iceland's last whaling company, Hvalur hf. Paul Watson, a co-founder of Greenpeace and founder of Sea Shepherd, has a history of intervening in Icelandic whaling operations - In 1986, members of his group successfully reduced the whaling fleet of Hvalur hf by half.

Key Points: 
  • ALBERT DOCK, HULL, England, April 16, 2024 /PRNewswire/ -- Captain Paul Watson Foundation is launching Operation Ice Storm from Albert Dock in Yorkshire to directly oppose Iceland's last whaling company, Hvalur hf.
  • "The time is up for the world's most notorious hunter of whales, Kristján Loftsson," stated Captain Paul Watson, who will lead this summer's anti-whaling campaign on his flagship the John Paul DeJoria, a 72-meter former Scottish Fisheries Protection Vessel.
  • The whaler's business empire includes large shareholdings in banks and IT companies and the magnate uses his wealth to hunt up to 209 fin whales each season.
  • Fin whales are protected under international conservation law and listed as vulnerable on the IUCN Red List of Threatened Species.

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

Retrieved on: 
Martedì, Aprile 9, 2024
HER2, CD8, Phosphorylation, Survival, Cholangiocarcinoma, Immunotherapy, RECIST, Oncology, MAST, Patient, City, Degranulation, ASX, ADCC, Cancer, Hope, Overalls, Pembrolizumab, PRS, AACR, SPECT, Vaccination, Melanoma, Recurrence, PD-L1, IMU, Medical imaging

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.

Key Points: 
  • Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.
  • SYDNEY, Australia, April 09, 2024 (GLOBE NEWSWIRE) -- Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in San Diego, CA.
  • HER-Vaxx induced HER2-specific antibodies able to mediate antibody-dependent cell cytotoxicity (ADCC) and inhibit intracellular HER2 phosphorylation and correlated with tumour reduction.
  • The HER-Vaxx induced HER2-specific antibodies demonstrate a similar mechanism of action to HERCEPTINâ validating B cell immunotherapy as an alternative anti-cancer agent to monoclonal antibodies.

BEVM Bitcoin Layer2 Closes Seed Round with RockTree Capital, Sathoshi Lab & 20 Others

Retrieved on: 
Mercoledì, Marzo 27, 2024
Consensus, EVM, MAST, Consensus decision-making, Capital, Financial regulation, Architecture, DBFX, BTC, Ecosystem, Traction, Safety, Geography, Cryptocurrency

Singapore, Singapore, March 27, 2024 (GLOBE NEWSWIRE) -- The Bitcoin Layer2 project BEVM has announced the completion of its seed round, and also a part of its Series A round, raising tens of million USD.

Key Points: 
  • Singapore, Singapore, March 27, 2024 (GLOBE NEWSWIRE) -- The Bitcoin Layer2 project BEVM has announced the completion of its seed round, and also a part of its Series A round, raising tens of million USD.
  • BEVM is the first EVM-compatible Bitcoin Layer2 network built on Taproot Consensus and uses $BTC as gas, aiming to bring 10% of $BTC into its Layer2 network environment.
  • Gavin Guo, Core Builder of BEVM said “Taproot Consensus is the final result of our team’s six years of exploring Bitcoin Layer2 solutions.
  • BEVM is currently the most decentralized and secure BTC layer2 solution.”
    BEVM has already implemented decentralized Bitcoin cross-chain custody services through Schnorr Signature, MAST and Bitcoin SPVs.

Agilent Brings Great Science to Life at Analytica 2024

Retrieved on: 
Giovedì, Aprile 4, 2024
Technology, Chemicals, Plastics, Health, Manufacturing, Batteries, Alternative Energy, Energy, Machinery, Research, Software, Health Technology, Hardware, Science, Semiconductor, Online, Immersion, Automation, Sustainable energy, Advanced Materials, Biotechnology, PFAS, Bioreactor, Environment, Biophysical environment, ICP-OES, MAST, Tissue, Food, ADS, Molecular biology, Laboratory, ICP-MS, Merck Group, Workflow, Agilent Technologies, Water, Chemical substance, BioTek, Fine chemical

Agilent Technologies Inc. (NYSE: A) today announced its participation in Analytica 2024, where it will unveil its latest innovations and transformative workflows.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced its participation in Analytica 2024, where it will unveil its latest innovations and transformative workflows.
  • Analytica, the premier international trade fair for laboratory technology, analysis, and biotechnology, is scheduled to take place from April 9 to 12 in Munich, Germany.
  • Agilent technical experts will be available to share insights into these latest innovations and intuitive workflows.
  • Join us as we bring Great Science to Life!

Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts

Retrieved on: 
Giovedì, Febbraio 22, 2024
Allotransplantation, Skin cancer, Cholangiocarcinoma, Fast track (FDA), NHL, Melanoma, FDA, Pembrolizumab, CD19, Rupture, Lung, Epidemiology, Breast, Safety, Neoplasm, ASX, Bone marrow, Patient, RECIST, MAST, National library, IMU, Blinatumomab, DLBCL, Cancer, BTC, Vaccine

Imugene Managing Director & CEO Leslie Chong said: “We are encouraged by the initial safety and efficacy signals seen to date.

Key Points: 
  • Imugene Managing Director & CEO Leslie Chong said: “We are encouraged by the initial safety and efficacy signals seen to date.
  • Notably, in our Phase 1 MAST CF33 oncolytic virus trial, we’ve seen encouraging response rates during dose escalation, including one complete response in a patient with cholangiocarcinoma, and two partial responses in melanoma as we continue to dose escalate with no safety issues.
  • Importantly, two out of three of these responses were achieved with CF33 monotherapy.
  • onCARlytics uses an antigen/target-armed CF33, followed by treatment with a CD19 targeting therapy directed against that antigen or target.

Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023

Retrieved on: 
Mercoledì, Novembre 22, 2023
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, American Cancer Society, PSA, Disease, Urology, Patient, Prostate cancer, MAST, Neoplasm, Prostate-specific antigen, Physician, SUO, Society, Biopsy, Medical imaging, Lace

Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment.
  • Collectively, the posters will report data from more than 60,000 patients.
  • The American Cancer Society estimates that there will be nearly 290,000 new cases of prostate cancer in the U.S. this year.
  • An ongoing challenge in the management of prostate cancer is distinguishing between patients whose tumors require careful monitoring, known as active surveillance, and those who require intervention.

Mobile Application Security Testing Market worth $3.2 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Giovedì, Dicembre 14, 2023
Cloud, Data management, Acquisition, Research, IPad, Organization, Software, Privacy, IPod Touch, IBM, Knowledge, OpenText, Intellectual property, NowSecure, MAST, CE, API, HCL, Growth, App Store (iOS/iPadOS), OS, IOS, IPhone, MEA, Fintech, Architecture, Mobile phone, Retail, Medical device, Online shopping, Risk management, Mobile, Apple, Apptio

Mobile application security testing adoption in large organizations has witnessed a notable upward trend in recent years.

Key Points: 
  • Mobile application security testing adoption in large organizations has witnessed a notable upward trend in recent years.
  • Large organizations are investing in robust mobile application security testing practices to identify and mitigate vulnerabilities proactively.
  • Top Key Companies in Mobile Application Security Testing Market:
    August 2023 - Synopsys announced two new collaboration agreements with NowSecure, recognized experts in mobile security and privacy, and Secure Code Warrior, provider of the leading agile learning platform for developer-driven security, to expand its Software Integrity Group's industry-leading portfolio of application security testing (AST) solutions.
  • Mobile Application Security Testing Market Advantages:
    MAST aids in locating holes and weak points in the architecture, design, and coding of mobile applications.